Biopharmas get off to a good start with drug approvals in Q1

One of the metrics used to gauge the industry's progress is the number of new medicines that receive regulatory approval annually. The returns from the first quarter indicate that the innovation engine is in good shape and biopharma companies appear to be on pace to match the totals they achieved in the past couple of years.